Kanghui Sells Spare Assets for 100 Million Yuan to Buy Time for Its AI Shift
Kanghui Co., a Chinese listed company that spent years in pharmaceuticals before pivoting toward computing power, has agreed to sell idle assets for about 100 million yuan, a disposal expected to add roughly 55 million yuan to its profit. The transaction is small in national terms but unusually revealing: it shows how a mid-sized Chinese firm manages the awkward middle of a business model change, when the old business still pays the bills and the new one has not yet started.
The pattern is familiar across China’s listed small caps. A company announces a strategic pivot, signs cooperation agreements, and then faces the harder question of what the income statement looks like while the new business is being built. Selling assets that are not earning their keep is one of the few levers available. The gain lands in the profit line, smoothing results for a reporting period that might otherwise look weak.
According to reporting on the deal, the disposal is one part of a broader repositioning that has been underway since the company changed hands more than a year ago. Three strands run in parallel: asset sales that generate one-time gains, a push to move computing power from the signing stage into operational delivery, and a reshuffling of the original pharmaceutical assets. Each strand serves a different audience — the first the quarterly numbers, the second investors looking for growth, the third the legacy business that still generates revenue.
The computing angle is the one that draws attention. China’s demand for data center capacity and rented processing power has grown quickly, and a long list of companies with no technology background have tried to attach themselves to it. Some have built real facilities and real customers. Others have announced plans that never quite arrive. The distance between a signed agreement and a paying customer is where most of these stories are decided, and it is the gap the company now says it is closing.
For global readers, the episode is a window into how Chinese corporate reinvention actually works. It is rarely a single dramatic announcement. It is a sequence of small financial moves — a sale here, a writedown there, a subsidiary renamed — that together shift a company’s center of gravity while keeping it listed and financed. Asset disposals are the most common tool because they are fast, require no new capital, and produce a clean accounting gain.
The risk is that one-time gains flatter a business without fixing it. A 55 million yuan boost helps a profit statement once. It does not create recurring revenue, and it does not prove that computing capacity can be sold at a margin. Investors who have watched similar pivots elsewhere in China’s small-cap market tend to look past the headline number to the operating detail: how much capacity is actually running, who is paying for it, and at what price.
What makes this case worth following is the transparency of the trade-off. The company is not pretending the asset sale is growth. It is using balance-sheet room to buy time, while the pharmaceutical legacy is rearranged and the computing business is expected to start delivering. Whether that time is used well will show up in the next few reporting periods, in the mix between one-off items and revenue that repeats.